Video Journal of Oncology (VJOncology)’s Post

#Biophotonics innovation in #healthcare: A recent study explores the potential of multispectral autofluorescence imaging for early detection of oral cancer. By analyzing fluorescence patterns in oral lesions, researchers using #MachineLearning achieved 85% sensitivity and 78% accuracy in distinguishing cancerous/precancerous from benign lesions. This technology marks a promising step towards more effective diagnostic tools in oral healthcare. Read about the study's findings, and implications for clinical practice, in the new SPIE journal #BiophotonicsDiscovery: https://lnkd.in/gG-RzaiS

💡 Our research grants are critically important to moving desmoid tumor science forward for the good of patients. The DTRF is the only foundation in the country solely dedicated to funding desmoid tumor research and finding a cure for each and every patient. At the September 2023 DTRF International Research Workshop and DTRF Scientific & Medical Advisory Board meeting, a key research priority was identified: learning why some desmoid tumors spontaneously regress. The 2024 grant cycle is for a planning grant to develop teams and/or preliminary data toward a larger grant to address questions around spontaneous tumor regression. 🔗 Please read the RFP guidelines for more information: https://lnkd.in/e83BcQpg Full Grant Application Deadline: Friday, June 14, 2024. Please direct any questions to us at research@dtrf.org. #research #DTRF #DesmoidTumorResearchFoundation #desmoid #desmoidtumor #desmoidawareness #aggressivefibromatosis #Desmoidian #desmoidresearch

When diagnosing ILD, the radiologist is your best friend. It is a diagnosis of exclusion, warranting careful correlation of radiologic patterns with clinical features. If adequately diagnosed, it can save lives, and allow patients to stay on highly effective anticancer drugs for longer. Proud to share our latest educational article, just out in Insights Into Imaging, delving deep into the radiologist’s role in detecting cancer treatment related ILD. In the article, we highlight the patophysiology, radiologic patterns and best practices for the diagnosis, monitoring and management of this important condition. Open Access Link (download a copy!): https://lnkd.in/dVP8rNTY

In a comparative sensitivity study of neuroendocrine neoplasms (NEN), Synaptophysin exhibited the highest sensitivity at 93.3%, followed by INSM1 at 89.2% and chromogranin A at 87.5%. KEY NOTE: Unlike Synaptophysin and Chromogranin A, INSM-1(MRQ-70) expresses in the Nuclei for a much cleaner Interpretation! 😍 #IHC #Immunohistochemistry #Histology #Pathology

Join us for an exclusive webinar, Rethinking Solid Tumor Profiling: How Utilizing Complementary Technologies Can Allow Laboratories to Guide Better Treatment Decisions, in partnership with GenomeWeb on March 27, 2024, at 1:00 PM EDT. Discover how Houston Methodist Hospital leverages NGS and MassARRAY technologies to guide better treatment decisions for lung adenocarcinoma. In this webinar presented by Dr. Jessica Thomas, Associate Medical Director at the Molecular Pathology Diagnostic Laboratory, Houston Methodist Hospital, your gain knowledge on the impact of integrating complementary technologies on accelerating results and improving success rates for low cellularity samples. Register now, even if you can’t attend, we’ll send you the recording and key takeaways! https://lnkd.in/g7xnxXAP Whether you're a hospital, cancer center, or molecular pathologist interested in improving the patient diagnostic journey, this webinar will provide valuable perspectives on the latest strategies for implementing a testing paradigm for solid tumor profiling in your own laboratory. #SolidTumorProfiling #GenomicMedicine #MolecularProfiling #OncologyInnovation #MolecularDiagnostics #MolecularTestingLab #LungCancer #MedicalWebinar #Pathology

A vital meta-analysis featured in BMJ Open examines the efficacy of contrast-enhanced MRI (CEMRI) and CT (CECT) in monitoring hepatocellular carcinoma (HCC) post-transarterial chemoembolization (TACE). The study scrutinizes 5843 patient cases across 36 studies, revealing that CEMRI not only demonstrates high sensitivity and specificity but also exceeds CECT in overall diagnostic value. This finding emphasizes CEMRI's superior ability to guide clinicians in treatment responses, potentially leading to more informed and effective patient care decisions. As the study suggests, investing in advanced imaging technologies like MRI could be pivotal in enhancing cancer treatment outcomes. #InnovationInHealthcare #MRIvsCT #PatientOutcomes

🔬 Celnovte's TTF1 (C7H7) Antibody Achieves Optimal Performance in NordiQC Assessment 🔬 ✅ Key usages of TTF1 marker in IHC: - Diagnosing primary lung adenocarcinoma. - Differentiating between lung and non-lung tumors. - Identifying thyroid transcription factor-1 in thyroid carcinomas. - Assessing neuroendocrine tumors of the lung. - Investigating lineage-specific markers in pulmonary and thyroid tissues. - Studying TTF1 expression in normal and malignant tissues in basic and clinical research. Enhance your research and diagnostic precision with the TTF1 marker. #Pathology #IHC #Immunohistochemistry #CancerResearch #LungAdenocarcinoma #TTF1 #celnovte #primaryantibody

At J&J, one of my biggest motivators are the people within the wider healthcare community who share our tireless dedication and determination to bring transformative medicines to patients. An article published in The Pathologist from Ales Ryska, Chair, Department of Pathology, Charles University Medical Faculty, Hradec Králové, Czech Republic, shares key insights on how we can collaboratively make targeted treatments a reality for more cancer patients. Precision medicine holds promise in revolutionising the care landscape, and we must work collectively to make sure that all people living with cancer have access to biomarker testing and treatments that aim to target their unique disease characteristics. Have a read here: https://bit.ly/3XFXbII #PrecisionMedicine #BiomarkerTesting #Oncology

🎇 New research reveals the mechanism of cachexia:   Cachexia affects more than half of cancer patients, leading to 20% of deaths. A key feature is adipose atrophy, yet its underlying mechanism remains unclear. A recent article published in Signal Transduction and Targeted Therapy, using mouse models, demonstrated that white adipose tissue browning may be an early manifestation of cachexia, preceding weight loss and muscle wasting. Through analysis of extraular vesicle proteins from tumor s, GRP75 was identified as a key mediator of adipocyte browning. GRP75 binds to ANT2, enhancing its interaction with uncoupling protein 1, thereby promoting browning. The GRP75 inhibitor withanone can reverse this process and alleviate cachexia. 💐 💐 💐   This study unveils a novel mechanism by which GRP75 regulates adipocyte browning, providing a new target for early intervention in cachexia. 🌺 🌺 🌺   https://lnkd.in/eqWKHn94   For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7   Related Product Recommendation:   #Withanone (https://lnkd.in/ejSQHhkd);   #ProteinA/GMagneticBeads (https://lnkd.in/gmMKcw8c);   #AntiFlagMagneticBeads (https://lnkd.in/gi-ixv8z);   #AntiGSTMagneticBeads (https://lnkd.in/gQn7Qg6r);   #Dexamethasone (Hexadecadrol; Prednisolone F; https://lnkd.in/gwxAJ7p8);   #Isobutylmethylxanthine (3-Isobutyl-1-methylxanthine; IBMX; https://lnkd.in/gu_GMWSF)   #SignalTransductionAndTargetedTherapy #GRP75 #Cachexia #MCE #MedChemExpress

Unraveling the intricate interplay of cells within tumors requires innovative tools. Multiplex Immunofluorescence (mIF) offers a powerful solution, enabling researchers to visualize immune cell dynamics, comprehend tumor heterogeneity, and accelerate groundbreaking discoveries. By transcending the limitations of traditional methods, mIF unveils hidden patterns that influence treatment response. Ready to revolutionize immuno-oncology? Let's collaborate! www.icuradx.com client_request@icuradx.com #immunooncology #tumormicroenvironment #mIF #precisionmedicine #spatialbiology